Venetoclax
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Blastic Plasmacytoid Dendritic Cell Neoplasm
Conditions
Blastic Plasmacytoid Dendritic Cell Neoplasm
Trial Timeline
Aug 23, 2018 → Apr 16, 2025
NCT ID
NCT03485547About Venetoclax
Venetoclax is a phase 1 stage product being developed by AbbVie for Blastic Plasmacytoid Dendritic Cell Neoplasm. The current trial status is completed. This product is registered under clinical trial identifier NCT03485547. Target conditions include Blastic Plasmacytoid Dendritic Cell Neoplasm.
What happened to similar drugs?
2 of 13 similar drugs in Blastic Plasmacytoid Dendritic Cell Neoplasm were approved
Approved (2) Terminated (3) Active (9)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (16)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03123029 | Pre-clinical | Active |
| NCT07387471 | Phase 2 | Recruiting |
| NCT06742086 | Phase 1 | Completed |
| NCT06070948 | Phase 1 | Withdrawn |
| NCT05768711 | Phase 2 | Active |
| NCT05701215 | Phase 2 | Active |
| NCT05909553 | Phase 1 | Completed |
| NCT04810598 | Phase 1 | Completed |
| NCT03844048 | Phase 3 | Active |
| NCT03873857 | Pre-clinical | Completed |
| NCT03567876 | Phase 2 | Completed |
| NCT03485547 | Phase 1 | Completed |
| NCT02966756 | Phase 2 | Recruiting |
| NCT02980731 | Phase 3 | Completed |
| NCT02756611 | Phase 3 | Completed |
| NCT02141282 | Phase 2 | Completed |
Competing Products
20 competing products in Blastic Plasmacytoid Dendritic Cell Neoplasm